first
isol
c
pneumonia
serendipit
obtain
trachoma
studi
recoveri
similar
isol
respiratori
tract
colleg
student
pneumonia
seattl
grayston
colleagu
appli
design
twar
first
two
isol
one
serotyp
c
pneumonia
identifi
far
studi
found
high
degre
genet
related
greater
among
human
c
pneumonia
isol
test
microbiolog
chlamydia
gramneg
envelop
without
detect
peptidoglycan
howev
recent
genom
analysi
reveal
c
trachomati
c
pneumonia
encod
protein
form
nearli
complet
pathway
synthesi
peptidoglycan
includ
penicillinbind
protein
chlamydia
also
share
groupspecif
lipopolysaccharid
antigen
use
host
adenosin
triphosph
atp
synthesi
chlamydi
protein
although
chlamydia
auxotroph
three
four
nucleosid
triphosph
encod
function
glucosecatabol
enzym
use
gener
atp
peptidoglycan
synthesi
reason
gene
turn
may
relat
adapt
intracellular
environ
chlamydia
also
encod
abund
protein
call
major
outer
membran
protein
momp
ompa
surfac
expos
c
trachomati
c
psittaci
appar
c
pneumonia
momp
major
determin
serolog
classif
c
trachomati
c
psittaci
isol
chlamydia
suscept
antibiot
interfer
dna
protein
synthesi
includ
tetracyclin
macrolid
quinolon
c
pneumonia
lack
tryptophan
recoveri
biosynthesi
pathway
resist
sulfonamid
trimethoprim
chlamydia
uniqu
development
cycl
morpholog
distinct
infecti
reproduct
form
elementari
bodi
eb
reticul
bodi
rb
fig
infect
infecti
eb
nm
diamet
attach
host
cell
process
electrostat
bind
taken
cell
endocytosi
depend
microtubul
system
oblig
intracellular
bacterium
must
grown
tissu
cultur
capabl
caus
persist
infect
often
subclin
worldwid
distribut
infect
mani
anim
well
human
primarili
respiratori
pathogen
human
caus
communityacquir
pneumonia
caus
epidem
enclos
popul
militari
base
school
nurs
home
chlamydia
pneumonia
caus
pneumonia
clinic
differenti
caus
atyp
pneumonia
especi
mycoplasma
pneumonia
accur
method
diagnosi
identif
organ
respiratori
sampl
cultur
nucleic
acid
amplif
test
naat
serolog
limit
valu
requir
pair
sera
mani
patient
posit
cultur
naat
seroneg
c
pneumonia
suscept
macrolid
quinolon
tetracyclin
data
efficaci
limit
includ
optim
dose
durat
therapi
tento
cours
erythromycin
clarithromycin
doxycyclin
levofloxacin
moxifloxacin
day
azithromycin
clinic
effect
result
approxim
microbiolog
erad
aberr
inclus
averag
diamet
contain
ab
similar
size
normal
rb
appear
electron
dens
longer
retain
smooth
spheric
shape
dens
ab
retain
characterist
chlamydi
outer
membran
structur
littl
periplasm
space
membran
tightli
bound
chlamydi
bodi
similar
normal
rb
eb
observ
inclus
find
show
development
cycl
c
pneumonia
combin
typic
develop
form
persist
phase
tissu
cultur
anoth
possibl
mechan
chlamydi
persist
could
direct
effect
host
cell
possibl
effect
apoptosi
import
regul
cell
growth
tissu
develop
apoptosi
genet
program
tightli
control
process
unlik
necrosi
involv
nonspecif
inflamm
tissu
damag
intracellular
enzym
condens
nucleu
cytoplasm
fragment
mani
microbi
pathogen
includ
chlamydia
found
modul
cellular
apoptosi
surviv
multipli
chlamydia
spp
shown
induc
inhibit
host
cell
apoptosi
depend
stage
chlamydi
development
cycl
chlamydia
protect
infect
cell
apoptosi
result
extern
stimuli
earli
stage
infect
may
induc
apoptosi
host
cell
later
stage
life
cycl
thu
chlamydia
may
protect
infect
cell
cytotox
mechan
immun
system
apoptosi
observ
end
infect
cycl
may
contribut
inflammatori
respons
apoptot
cell
secret
proinflammatori
cytokin
facilit
releas
organ
infect
cell
studi
cultur
report
cell
infect
c
trachomati
c
pneumonia
resist
apoptosi
result
extern
ligand
via
inhibit
caspac
activ
data
studi
longterm
continu
infect
cell
model
show
mark
differ
effect
c
pneumonia
apoptosi
acut
chronic
infect
cell
acut
c
pneumonia
infect
induc
apoptot
chang
cell
within
first
hour
infect
induct
apoptosi
acut
infect
may
facilit
releas
c
pneumonia
host
cell
chronic
c
pneumonia
infect
inhibit
apoptot
chang
within
first
hour
day
result
suggest
inhibit
apoptosi
may
help
protect
organ
intracellular
persist
state
although
numer
method
use
detect
c
pneumonia
clinic
sampl
practic
detect
difficult
primarili
lack
standard
wellvalid
method
determin
whether
c
pneumonia
infect
acut
primari
infect
reinfect
chronic
persist
stage
past
infect
also
difficult
cell
cultur
immunohistochemistri
ihc
nucleic
acid
amplif
test
naat
detect
live
bacteria
antigen
nucleic
acid
respect
techniqu
primarili
use
research
set
requir
experienc
special
laboratori
clinic
set
routin
diagnosi
c
pneumonia
infect
base
result
serolog
test
identifi
antic
pneumonia
immunoglobulin
g
igg
iga
igm
antibodi
approach
problemat
number
reason
subsequ
outlin
detail
recent
new
polymeras
chain
reaction
pcr
assay
detect
c
pneumonia
becam
commerci
avail
clear
us
food
drug
administr
fda
juli
discuss
later
futur
use
assay
provid
new
diagnost
capabl
c
pneumonia
oblig
intracellular
parasit
isol
mean
cell
cultur
organ
fastidi
slow
grow
c
pneumonia
grow
although
readili
cell
line
usual
suscept
c
trachomati
mccoy
hela
cell
growth
observ
somewhat
easier
hl
human
line
cell
c
pneumonia
isol
respiratori
tract
nasopharyng
throat
cultur
bronchoalveolar
lavag
fluid
eb
sporelik
metabol
inact
stabl
extracellular
environ
within
host
cell
eb
remain
within
membranelin
phagosom
inhibit
phagosomallysosom
fusion
inclus
membran
devoid
host
cell
marker
lipid
marker
traffic
inclus
suggest
function
interact
golgi
apparatu
chlamydia
appear
circumv
host
endocyt
pathway
inhabit
nonacid
vacuol
dissoci
late
endosom
lysosom
eb
differenti
rb
undergo
binari
fission
approxim
hour
rb
differenti
back
eb
despit
accumul
infecti
eb
inclus
host
cell
function
minim
disrupt
hour
releas
may
occur
via
cytolysi
process
exocytosi
extrus
whole
inclus
leav
host
cell
intact
strategi
success
enabl
organ
caus
essenti
silent
chronic
infect
number
vitro
studi
challeng
biphas
paradigm
chlamydia
may
enter
persist
state
vitro
treatment
certain
cytokin
treatment
antibiot
specif
penicillin
restrict
certain
nutrient
includ
iron
glucos
amino
acid
infect
monocyt
heat
shock
persist
state
metabol
activ
reduc
organ
often
refractori
antibiot
treatment
differ
system
produc
similar
growth
characterist
includ
loss
infect
develop
small
inclus
contain
fewer
eb
rb
ultrastuctur
find
specif
morpholog
abnorm
rb
suggest
somehow
alter
otherwis
normal
develop
abnorm
rb
often
call
aberr
bodi
ab
restrict
certain
nutrient
also
shown
induc
persist
chlamydia
ultrastructur
analysi
c
pneumonia
also
reveal
atyp
inclus
contain
larg
reticulatelik
ab
evid
redifferenti
eb
anoth
model
persist
c
pneumonia
infect
longterm
continu
infect
contrast
previous
describ
model
continu
cultur
becom
spontan
persist
chlamydia
host
cell
multipli
freeli
absenc
stress
c
pneumonia
infect
maintain
cell
year
without
centrifug
addit
cycloheximid
infect
level
infect
cell
high
ultrastructur
studi
reveal
three
type
inclus
cell
approxim
typic
larg
inclus
rang
approxim
diamet
second
type
alter
inclus
contain
normal
eb
rb
consider
lower
number
typic
inclus
pleomorph
ab
four
five
time
size
normal
rb
diamet
cytoplasm
homogen
third
type
inclus
small
multipl
inhous
naat
pcr
methodolog
publish
literatur
confound
lack
standard
valid
center
diseas
control
prevent
cdc
workshop
suggest
assay
consid
valid
enough
use
research
includ
earli
develop
valid
one
improv
other
develop
sinc
advantag
naat
pcr
assay
sensit
decreas
possibl
contamin
abil
quantifi
dna
nearli
decad
later
howev
mani
test
turn
highli
prone
falseposit
result
recent
singl
naat
detect
c
pneumonia
commerci
avail
list
vitro
diagnost
ivd
databas
fda
wwwaccessdatafdagov
scriptscdrhcfdocscfivdindexcfm
numer
inhous
pcrbase
test
still
perform
assay
rang
well
valid
valid
although
naat
offer
promis
exquisit
sensit
theoret
allow
detect
singl
organ
clinic
sampl
falseneg
posit
result
occur
larg
number
technic
issu
summar
recent
current
realtim
pcr
rtpcr
technolog
detect
c
pneumonia
use
rtpcr
offer
signific
advantag
convent
pcr
rapid
eas
autom
potenti
decreas
risk
carryov
contamin
potenti
provis
quantit
result
recent
commerci
avail
naat
assay
abbott
laboratori
abbott
park
il
develop
researchuseonli
pcr
assay
use
multicent
studi
compar
pcr
result
use
inhous
pcr
five
differ
laboratori
assay
perform
well
never
taken
clinic
trial
becton
dickinson
franklin
lake
nj
perform
clinic
trial
strand
displac
assay
clear
fda
biofir
technolog
formerli
idaho
technolog
salt
lake
citi
ut
develop
filmarray
assay
detect
virus
fda
clear
filmarray
system
includ
assay
platform
atyp
agent
pneumonia
includ
c
pneumonia
mycoplasma
pneumonia
bordetella
pertussi
assay
receiv
fda
clearanc
juli
filmarray
system
combin
nucleic
acid
extract
nest
pcr
detect
data
analysi
singleus
pouch
autom
system
simpl
perform
result
readi
hour
singl
test
platform
enabl
detect
numer
viral
bacteri
respiratori
pathogen
singl
test
water
ad
hydrat
lyophil
reagent
respiratori
specimen
ad
pouch
load
filmarray
instrument
remaind
test
complet
autom
extract
nucleic
acid
nest
pcr
reaction
perform
within
pouch
entir
close
system
firststep
pcr
multiplex
reaction
contain
primer
viral
bacteri
target
amplicon
first
pcr
dilut
second
round
pcr
reaction
perform
multiwel
array
well
contain
singl
primer
set
target
specif
pathogen
amplif
melt
curv
analysi
allow
filmarray
softwar
gener
result
target
system
robust
detect
low
concentr
pathogen
presenc
high
concentr
second
pathogen
result
avail
hour
respiratori
panel
detect
adenovirus
bocavirus
coronavirus
influenza
b
influenza
subtyp
novel
metapneumoviru
parainfluenza
virus
respiratori
syncyti
viru
rhinovirus
well
b
pertussi
c
pneumonia
pneumonia
specimen
research
pcr
test
includ
nasopharyng
swab
secret
respiratori
tract
includ
sputum
bronchoalveolar
lavag
fluid
bal
tissu
peripher
blood
mononuclear
cell
swab
sent
tube
without
transport
medium
sputum
bal
tissu
also
collect
steril
devic
without
transport
medium
necessari
sputum
dilut
homogen
trisedta
tri
hydroxymethyl
aminomethaneethylenediaminetetraacet
acid
buffer
tissu
homogen
dna
extract
dna
extract
pcr
tissu
biopsi
includ
lung
adenoid
organ
also
isol
sputum
sputum
toxic
cell
cultur
often
contamin
overgrow
fungi
bacteria
nasopharyng
pharyng
swab
specimen
collect
use
aluminum
plasticshaft
dacron
tip
swab
mandatori
calcium
algin
cotton
tip
wooden
shaft
may
inhibit
growth
organ
tissu
cultur
may
toxic
cell
specimen
cultur
must
store
suitabl
transport
medium
optim
chlamydia
suitabl
medium
sucrosephosph
glutam
spg
buffer
antibiot
fetal
calf
serum
readytous
media
also
commerci
avail
specimen
process
within
hour
kept
refriger
c
ship
wet
ice
sampl
process
within
hour
held
c
freez
c
rapid
freez
decreas
titer
viabl
organ
specimen
need
treat
steril
glass
bead
sonic
disrupt
cell
centrifug
onto
cell
monolay
facilit
absorpt
cell
cultur
incub
c
carbon
dioxid
least
hour
per
passag
cultur
confirm
assess
stain
inclus
bodi
use
chlamydia
genusspecif
fluoresc
antibodi
epifluoresc
microscopi
fig
one
subcultur
may
necessari
isol
thu
cultur
straightforward
attempt
diagnos
microorgan
time
fashion
organ
difficult
grow
lack
commerci
avail
diagnost
assay
origin
associ
respiratori
diseas
use
serolog
microimmunofluoresc
mif
test
patient
igg
autoantibodi
igm
may
cross
react
antic
pneumonia
igm
antibodi
c
pneumonia
also
detect
tissu
section
cell
monoclon
antibodi
label
peroxidas
ihc
fluoresc
immunofluoresc
marker
antigen
detect
test
gener
allow
preserv
tissu
morpholog
hand
interpret
stain
pattern
distinguish
organ
background
nonspecif
stain
subject
influenc
number
technic
issu
complex
biolog
sampl
ihc
give
rise
crossreact
antitarget
antibodi
nontarget
protein
produc
nonspecif
signal
eg
immunoreact
c
pneumonia
frequent
present
atheroma
nonatheroma
section
vessel
wall
site
posit
result
c
pneumonia
ihc
assay
precis
match
site
autofluoresc
ceroid
deposit
interpret
ihc
stain
must
perform
utmost
caution
summari
serolog
seem
insuffici
diagnosi
c
pneumonia
respiratori
tract
infect
also
inadequ
methodolog
studi
associ
c
pneumonia
diseas
import
know
new
environment
chlamydia
spp
steadili
describ
ampl
evid
exist
huge
divers
wide
distribut
chlamydia
natur
human
expos
divers
speci
exampl
recoveri
novel
environment
chlamydia
strain
activ
sludg
cocultiv
acanthamoeba
sp
report
shown
also
invad
mammalian
cell
new
environment
chlamydia
ie
simkania
waddlia
parachlamydia
may
interfer
serolog
test
tradit
chlamydiacea
chlamydia
summari
c
pneumonia
serolog
problemat
term
defin
specif
reproduc
titer
given
clinic
pictur
diseas
even
prospect
defin
mode
transmiss
c
pneumonia
remain
uncertain
probabl
occur
infect
respiratori
secret
acquisit
infect
via
droplet
aerosol
describ
laboratori
accid
c
pneumonia
remain
viabl
formica
countertop
hour
surviv
smallparticl
aerosol
spread
within
famili
enclos
popul
includ
militari
recruit
prison
nurs
home
describ
sever
serolog
survey
document
rise
chlamydi
antibodi
preval
rate
begin
schoolag
children
reach
adolesc
seropreval
antibodi
determin
mif
method
exceed
adult
popul
proport
communityacquir
pneumonia
cap
children
adult
associ
c
pneumonia
infect
rang
vari
geograph
locat
age
group
examin
diagnost
method
use
tabl
proport
cap
attribut
c
pneumonia
appear
significantli
lower
studi
publish
whether
secondari
method
use
recent
studi
use
rtpcr
possibl
cycl
seen
pneumonia
unknown
four
studi
publish
divers
geograph
area
europ
africa
thailand
use
rtpcr
found
preval
c
pneumonia
infect
rang
compar
chines
studi
use
mif
serolog
patient
singl
serum
sampl
see
tabl
earli
studi
reli
serolog
suggest
infect
children
younger
year
rare
howev
subsequ
studi
cultur
pcr
assay
found
preval
rate
infect
children
beyond
earli
infanc
similar
found
adult
approxim
perform
within
hour
storag
c
suffici
otherwis
specimen
kept
least
c
sever
type
serolog
assay
current
commerci
avail
detect
antibodi
c
pneumonia
howev
none
current
approv
fda
indic
test
use
frequent
recommend
cdc
remain
mif
assay
test
base
enzymelink
immunosorb
assay
elisa
format
particularli
easi
perform
need
sophist
laboratori
equip
make
preferenti
offer
diagnost
chlamydi
tool
laboratori
c
pneumonia
howev
intracellular
pathogen
poor
correl
direct
detect
eg
cultur
naat
serolog
result
surpris
besid
specif
issu
clear
class
titer
antibodi
might
repres
acut
first
infect
reinfect
chronic
persist
past
c
pneumonia
infect
true
complement
fixat
test
measur
antibodi
chlamydi
lipopolysaccharidetherefor
specif
c
pneumonia
elisabas
test
purifi
c
pneumonia
eb
recombin
antigen
detect
specif
unclear
also
goldstandard
mif
test
formalin
c
pneumonia
eb
fix
onto
glass
slide
serolog
test
specif
antigen
use
crossreact
c
pneumonia
chlamydia
speci
shown
mif
test
factor
strain
type
puriti
concentr
antigen
use
assay
procedur
might
contribut
fact
mif
less
specif
c
pneumonia
thought
year
ago
data
also
show
signific
problem
subject
interpret
intralaboratori
interlaboratori
reproduc
problem
context
c
pneumonia
serolog
discuss
detail
two
recent
publish
review
articl
exampl
complex
issu
consid
two
multicent
pneumonia
treatment
studi
children
show
although
patient
studi
posit
cultur
result
met
serolog
criteria
mif
test
acut
infect
patient
patient
posit
cultur
result
met
serolog
criteria
approxim
posit
cultur
result
c
pneumonia
seroneg
benitez
cowork
report
similar
data
adult
investig
c
pneumonia
outbreak
prison
mif
serolog
igg
igm
posit
predict
valu
compar
rtpcr
anoth
problem
serolog
diagnosi
c
pneumonia
infect
mif
method
use
detect
serum
antibodi
standard
recent
studi
shown
substanti
interlaboratori
variat
perform
test
select
vitro
passag
c
pneumonia
subinhibitori
concentr
moxifloxacin
isol
found
point
mutat
gyra
gene
studi
longterm
continu
infect
cell
suggest
c
pneumonia
may
refractori
antibiot
persist
state
basi
data
follow
regimen
use
respiratori
infect
c
pneumonia
adult
doxycyclin
mg
oral
twice
daili
day
tetracyclin
mg
oral
four
time
daili
day
azithromycin
mg
day
follow
mgday
day
clarithromycin
mg
oral
twice
day
day
levofloxacin
mg
intraven
oral
day
day
moxifloxacin
mg
oral
day
day
children
erythromycin
suspens
mgkg
per
day
day
clarithromycin
suspens
mgkg
per
day
day
azithromycin
suspens
mgkg
first
day
follow
mgkg
daili
day
patient
may
need
retreat
one
distinguish
characterist
chlamydia
abil
caus
persist
often
subclin
infect
clinic
standpoint
chlamydia
may
persist
infect
par
excel
capabl
persist
host
month
year
often
without
caus
obviou
ill
microbiolog
standpoint
persist
also
refer
longterm
intracellular
infect
detect
antigen
microscopi
nucleic
acidbas
amplif
method
chronic
persist
infect
c
pneumonia
implic
pathogenesi
sever
chronic
diseas
initi
thought
infecti
includ
asthma
arthriti
atherosclerosi
howev
studi
associ
c
pneumonia
disord
hamper
difficulti
diagnosi
chronic
persist
infect
organ
turn
make
determin
efficaci
intervent
difficult
especi
antibiot
infect
c
pneumonia
link
asthma
larg
number
epidemiolog
clinic
studi
controversi
definit
infect
diagnost
test
contribut
difficulti
interpret
comparison
studi
field
complic
differ
studi
popul
regard
asthma
phenotyp
presenc
acut
symptom
tabl
summar
select
studi
examin
associ
c
pneumonia
infect
asthma
wide
rang
posit
illustr
sometim
contradictori
find
regard
associ
c
pneumonia
asthma
may
explain
differ
popul
diagnost
method
hahn
colleagu
report
associ
serolog
evid
acut
c
pneumonia
infect
adultonset
children
culturedocu
c
pneumonia
respiratori
infect
pneumonia
asthma
show
seroneg
mif
prolong
respiratori
infect
document
cultur
last
sever
week
sever
year
acut
infect
report
coinfect
organ
specif
streptococcu
pneumonia
pneumonia
may
occur
frequent
clinic
patient
differenti
infect
singl
organ
case
c
pneumonia
may
primari
caus
pneumonia
might
disrupt
normal
clearanc
mechan
enabl
pathogen
invad
may
case
outbreak
pneumonia
fatal
pneumococc
mening
among
us
armi
traine
six
traine
pneumonia
infect
c
pneumonia
suggest
simultan
outbreak
infect
asymptomat
respiratori
infect
may
occur
adult
children
role
asymptomat
carriag
play
epidemiolog
c
pneumonia
known
acut
respiratori
infect
c
pneumonia
appear
vari
season
systemat
surveil
c
pneumonia
infect
exist
unit
state
respiratori
infect
c
pneumonia
probabl
mild
asymptomat
initi
report
emphas
mild
atyp
pneumonia
clinic
resembl
associ
pneumonia
subsequ
studi
found
pneumonia
associ
c
pneumonia
clinic
indistinguish
pneumonia
c
pneumonia
associ
sever
ill
even
death
although
role
preexist
chronic
condit
contribut
factor
mani
patient
difficult
assess
c
pneumonia
seriou
pathogen
even
absenc
underli
diseas
c
pneumonia
isol
respiratori
tract
pleural
fluid
previous
healthi
adolesc
boy
sever
pneumonia
complic
respiratori
failur
pleural
effus
role
host
factor
remain
determin
although
c
pneumonia
detect
bronchoalveolar
lavag
fluid
group
patient
acquir
immunodefici
syndrom
pneumonia
clinic
role
patient
uncertain
coinfect
wellrecogn
pathogen
pneumocysti
jirovecii
mycobacterium
tuberculosi
gaydo
colleagu
identifi
c
pneumonia
infect
pcr
assay
group
immunocompromis
adult
human
immunodefici
infect
malign
neoplasm
immun
disord
includ
system
lupu
erythematosu
sarcoidosi
common
variabl
immunodefici
c
pneumonia
respons
episod
acut
chest
syndrom
children
sickl
cell
diseas
new
york
c
pneumonia
infect
patient
appear
associ
sever
hypoxia
infect
pneumonia
relationship
c
pneumonia
upper
respiratori
infect
includ
pharyng
sinus
otiti
media
less
clear
data
treatment
c
pneumonia
respiratori
infect
limit
c
pneumonia
suscept
antibiot
affect
dna
protein
synthesi
includ
macrolid
azalid
specif
azithromycin
tetracyclin
quinolon
tabl
howev
vitro
activ
may
alway
predict
vivo
efficaci
publish
pneumonia
treatment
studi
use
serolog
alon
diagnosi
c
pneumonia
infect
best
clinic
end
point
result
sever
multicent
treatment
studi
use
cultur
show
efficaci
treatment
erythromycin
clarithromycin
azithromycin
levofloxacin
moxifloxacin
erad
c
pneumonia
nasopharynx
children
adult
cap
patient
clinic
improv
despit
persist
organ
persist
appear
result
develop
antibiot
resist
minimum
inhibitori
concentr
mic
isol
obtain
treatment
chang
antibiot
resist
unusu
chlamydia
investig
unabl
select
macrolid
resist
passag
c
pneumonia
subinhibitori
concentr
azithromycin
contrast
resist
quinolon
wheez
antic
pneumonia
ige
children
infect
c
pneumonia
shown
suggest
respons
bacterium
patient
asthma
role
stress
host
genet
delay
suboptim
respons
chlamydi
infect
develop
complic
certain
individu
role
specif
c
pneumonia
antigen
elicit
harm
immun
respons
patient
asthma
current
unclear
infect
c
pneumonia
contribut
inflamm
patient
allerg
asthma
diagnosi
treatment
infect
import
interact
may
also
exist
c
pneumonia
infect
asthma
drug
treatment
asthma
exacerb
frequent
includ
system
steroid
shown
enhanc
vitro
infect
c
pneumonia
reflect
signific
increas
inclus
affect
vitro
activ
azithromycin
erythromycin
doxycyclin
c
pneumonia
sever
studi
address
question
whether
antibiot
treatment
c
pneumonia
infect
patient
asthma
lead
improv
diseas
activ
studi
design
complic
fact
macrolid
quinolon
tetracyclin
immunomodulatori
activ
independ
antimicrobi
activ
posit
treatment
outcom
may
therefor
result
antichlamydi
immunomodulatori
effect
combin
two
sever
uncontrol
studi
show
benefici
effect
antibiot
patient
asthma
proven
presum
c
pneumonia
infect
subsequ
placebocontrol
trial
attempt
confirm
benefit
suggest
preliminari
studi
placebocontrol
trial
roxithromycin
patient
asthma
seroposit
c
pneumonia
show
significantli
higher
morn
peak
expiratori
flow
treatment
group
end
treatment
subsequ
time
point
absenc
clear
evid
asthma
asthmat
bronchiti
unit
state
studi
shown
associ
lack
associ
presenc
antibodi
igg
igm
iga
higher
antibodi
titer
igg
c
pneumonia
asthma
report
sinc
varieti
popul
studi
use
direct
detect
method
cultur
pcr
consist
establish
role
c
pneumonia
exacerb
asthma
see
tabl
patient
stabl
asthma
symptom
evid
infect
c
pneumonia
pcr
alon
combin
pneumonia
may
suggest
chronic
infect
clinic
implic
c
pneumonia
infect
patient
asthma
acut
symptom
clear
obviou
concern
persist
presenc
pathogen
may
lead
ongo
inflamm
thu
contribut
sever
progress
asthma
current
minim
data
exist
examin
immunolog
basi
associ
c
pneumonia
asthma
patholog
persist
infect
c
pneumonia
shown
patient
asthma
might
result
insuffici
respons
patient
critic
clearanc
intracellular
bacterium
analog
correl
abnorm
host
immun
respons
c
trachomati
infect
tissu
sequela
similar
relationship
may
conceiv
exist
respiratori
infect
c
pneumonia
asthma
patholog
abnorm
cellular
immun
respons
respiratori
infect
c
pneumonia
patient
asthma
may
part
relat
genet
variat
immun
mediat
gene
genet
variat
tolllik
receptor
investig
major
factor
develop
asthma
may
relat
suscept
c
pneumonia
tolllik
receptor
mice
decreas
adapt
cell
respons
led
poor
control
respiratori
infect
c
muridarum
prolong
inflamm
differ
c
pneumonia
igg
antibodi
respons
seen
children
asthma
depend
variant
mannosebind
lectin
allel
associ
mice
vitro
studi
shown
c
pneumonia
infect
replic
within
monocyt
macrophag
vascular
endotheli
smooth
muscl
cell
import
compon
atherosclerot
plaqu
vitro
infect
also
result
oxid
cellular
lowdens
lipoprotein
product
proinflammatori
cytokin
involv
atherogenesi
includ
tumor
necrosi
transendotheli
migrat
neutrophil
monocyt
c
pneumonia
induc
human
macrophag
foam
cell
format
vitro
key
event
earli
atheroma
develop
howev
may
specif
key
compon
appear
chlamydi
lipopolysaccharid
conserv
chlamydi
speci
includ
c
trachomati
howev
singl
serolog
pcr
ih
assay
use
consist
across
studi
assay
standard
boman
hammerschlag
review
seroepidemiolog
studi
publish
found
great
deal
heterogen
among
studi
term
serolog
test
use
criteria
seroposit
studi
igg
iga
titer
use
indic
chronic
infect
other
criteria
use
indic
past
infect
nine
studi
use
mif
assay
inhous
test
antigen
use
specifi
four
mif
assay
remain
studi
use
varieti
method
includ
genusspecif
enzym
immunoassay
wholecel
immunofluoresc
state
previous
mif
assay
standard
subject
signific
oper
variat
background
seroposit
rate
gener
popul
often
exceed
also
make
demonstr
associ
presenc
c
pneumonia
antibodi
cad
difficult
earlier
casecontrol
studi
show
associ
gener
small
base
singl
serum
sampl
take
account
antibodi
titer
fluctuat
time
metaanalysi
studi
found
combin
odd
ratio
igg
iga
antibodi
respect
boman
hammerschlag
also
analyz
studi
publish
examin
sampl
atheromat
tissu
presenc
c
pneumonia
cultur
electron
microscopi
pcr
ih
overal
rate
detect
c
pneumonia
rang
posit
least
one
method
howev
specimen
analyz
one
method
preval
rate
specimen
posit
least
two
method
usual
ih
pcr
serolog
studi
major
variat
found
method
includ
antibodi
techniqu
ih
pcr
ih
also
found
problem
interpret
reproduc
studi
hoyman
colleagu
report
ceroid
insolubl
lipid
present
plaqu
could
caus
nonspecif
reaction
ih
extent
interlaboratori
variat
perform
pcr
shown
apfalt
colleagu
sent
panel
homogen
clinic
atheroma
specimen
carotid
coronari
control
specimen
nine
laboratori
europ
unit
state
detect
pcr
posit
rate
clinic
specimen
rang
three
laboratori
identifi
c
pneumonia
neg
control
specimen
concord
assay
one
specimen
subsequ
apfalt
colleagu
show
contamin
practic
imposs
avoid
nest
pcr
assay
ieven
hoyman
publish
analysi
studi
report
sinc
mani
use
rtpcr
found
predominantli
neg
rtpcr
much
less
subject
contamin
amplicon
carryov
ieven
hoyman
also
note
studi
serolog
done
addit
pcr
correl
found
presenc
c
pneumonia
atheroma
tissu
presenc
antic
pneumonia
antibodi
individu
patient
extrapol
observ
c
pneumonia
dissemin
system
mice
intranas
inocul
presenc
c
pneumonia
peripher
blood
mononuclear
cell
pbmc
suggest
act
surrog
marker
infect
c
pneumonia
individu
cardiovascular
diseas
studi
examin
presenc
c
pneumonia
dna
pbmc
publish
seen
studi
vascular
tissu
report
preval
rate
c
pneumonia
dna
patient
asthma
studi
persist
c
pneumonia
infect
one
could
conclud
treatment
effect
result
antiinflammatori
action
roxithromycin
disappear
stop
drug
doubleblind
random
placebocontrol
studi
telithromycin
patient
acut
exacerb
asthma
found
reduct
asthma
symptom
among
treat
activ
drug
howev
studi
could
adequ
assess
effect
infect
one
enrol
patient
posit
c
pneumonia
pcr
assay
upper
airway
sampl
similarli
random
control
studi
clarithromycin
number
asthma
patient
pcrposit
either
c
pneumonia
pneumonia
therefor
underpow
test
effect
clarithromycin
asthma
outcom
variabl
random
control
trial
minocyclin
patient
allerg
asthma
show
improv
asthma
symptom
reduc
total
serum
ige
benefici
effect
appear
result
respiratori
infect
c
pneumonia
seroposit
c
pneumonia
significantli
differ
patient
control
subject
patient
posit
nasopharyng
cultur
c
pneumonia
compar
studi
antibiot
treatment
patient
asthma
complic
use
differ
criteria
c
pneumonia
infect
statu
cultur
pcr
serolog
combin
test
use
nonstandard
method
unclear
definit
chronic
infect
studi
underpow
show
effect
infect
statu
conclus
although
diagnosi
treatment
c
pneumonia
infect
patient
asthma
sign
symptom
airway
infect
recommend
benefit
use
antibiot
activ
atyp
bacteria
patient
asthma
without
laboratori
evid
infect
remain
controversi
persist
c
pneumonia
infect
also
implic
pathogenesi
sever
chronic
diseas
initi
thought
infecti
includ
atherosclerosi
multipl
sclerosi
ms
tempor
arter
stroke
alzheim
diseas
lung
cancer
macular
degener
studi
mice
shown
c
pneumonia
dissemin
spleen
organ
respiratori
infect
via
macrophag
howev
effect
conclus
shown
occur
human
addit
studi
associ
c
pneumonia
disord
hamper
difficulti
diagnosi
chronic
persist
infect
organ
valid
serolog
surrog
marker
exist
chronic
c
pneumonia
infect
high
preval
chlamydi
infect
transient
immun
infect
make
differenti
persist
infect
reinfect
even
past
infect
difficult
turn
make
determin
efficaci
therapeut
intervent
difficult
convent
risk
factor
includ
cigarett
smoke
hypertens
high
serum
lipid
level
fulli
explain
incid
preval
distribut
coronari
arteri
diseas
cad
inflamm
vessel
wall
play
essenti
role
initi
progress
atherosclerosi
eros
fissur
eventu
ruptur
atheromat
plaqu
variou
marker
system
inflamm
includ
creactiv
protein
found
predict
futur
cardiovascular
event
includ
nonfat
fatal
myocardi
infarct
stroke
although
inflamm
present
exact
caus
still
known
infecti
agent
includ
cytomegaloviru
human
herpesvirus
enterovirus
helicobact
pylori
bacteria
involv
periodont
diseas
c
pneumonia
also
investig
possibl
caus
inflamm
first
report
suggest
possibl
associ
c
pneumonia
infect
cad
came
casecontrol
studi
finland
publish
show
patient
proven
cad
significantli
like
antibodi
c
pneumonia
control
subject
select
random
report
quickli
follow
addit
seroepidemiolog
studi
studi
identifi
c
pneumonia
atheroma
variou
method
includ
cultur
immunohistochem
stain
ih
pcr
anim
studi
shown
c
pneumonia
either
induc
enhanc
develop
atherosclerosi
mgday
per
month
year
durat
followup
rang
month
year
result
earlier
small
studi
patient
arm
favor
antibiot
remain
larg
studi
favor
placebo
end
point
includ
total
mortal
subsequ
myocardi
event
includ
infarct
unstabl
angina
also
relationship
found
outcom
c
pneumonia
serolog
statu
similar
analysi
similar
result
publish
baker
couch
number
possibl
reason
propos
failur
show
posit
effect
antibiot
treatment
includ
popul
studi
trial
design
durat
treatment
given
lack
reliabl
marker
endovascular
c
pneumonia
infect
larg
neg
result
recent
organ
detect
studi
addit
studi
unlik
show
benefit
longterm
antibiot
treatment
reduc
mortal
cardiovascular
event
patient
cad
past
year
differ
bacteria
virus
propos
associ
ms
result
often
inconsist
possibl
associ
c
pneumonia
ms
first
describ
case
studi
research
vanderbilt
univers
medic
center
vumc
studi
follow
seri
patient
vumc
research
claim
identifi
organ
cultur
pcr
hypothesi
c
pneumonia
might
caus
ms
clear
result
subsequ
studi
number
group
conflict
find
c
pneumonia
dna
approxim
cerebrospin
fluid
csf
specimen
patient
ms
approxim
csf
specimen
patient
neurolog
diseas
other
find
none
csf
brain
tissu
cultur
pcr
effort
deal
issu
laboratorytolaboratori
differ
method
use
detect
c
pneumonia
studi
ms
prospect
collect
csf
specimen
patient
ms
neurolog
diseas
sent
laboratori
vumc
john
hopkin
univers
jhu
univers
umea
uu
sweden
subsequ
also
cdc
thirti
specimen
patient
ms
control
specimen
test
none
posit
pcr
jhu
uu
cdc
csf
specimen
patient
ms
control
specimen
posit
pcr
vumc
reason
discrep
result
discuss
includ
poor
sensit
assay
use
jhu
uu
cdc
specif
problem
assay
use
vumc
primer
set
use
vumc
multicent
studi
analyz
cdc
found
high
sequenc
similar
human
dna
determin
blast
basic
local
align
search
tool
suggest
specif
c
pneumonia
pbmc
also
vari
significantli
patient
cad
healthi
blood
donor
kohlhepp
other
examin
pbmc
blood
donor
either
younger
year
older
year
sampl
divid
sent
two
differ
laboratori
test
c
pneumonia
dna
rt
touchdown
nest
pcr
assay
two
sampl
group
posit
one
laboratori
neg
second
none
sampl
group
posit
either
laboratori
studi
show
two
differ
laboratori
differ
extract
method
rtpcr
target
detect
c
pneumonia
dna
cohort
patient
evid
interlaboratori
discrep
found
two
specimen
recent
west
cowork
examin
pbmc
patient
angiogramdocu
coronari
arteri
diseas
age
gender
control
subject
presenc
c
pneumonia
dna
use
two
differ
rtpcr
assay
use
differ
genet
target
c
pneumonia
dna
detect
specimen
includ
serial
specimen
subset
patient
follow
month
background
preval
antic
pneumonia
igg
greater
equal
case
control
subject
result
initi
seroepidemiolog
organ
detect
studi
led
sever
preliminari
studi
investig
efficaci
antibiot
treatment
direct
c
pneumonia
prevent
secondari
cardiac
event
result
preliminari
studi
suggest
effect
underpow
rais
question
antibiot
regimen
use
method
identif
patient
c
pneumonia
infect
major
assumpt
mani
seroepidemiolog
studi
associ
c
pneumonia
atherosclerosi
chronic
condit
presenc
antic
pneumonia
antibodi
impli
presenc
organ
somewher
bodi
howev
earlier
studi
patient
respiratori
infect
often
found
poor
correl
serolog
isol
organ
respiratori
tract
gupta
other
random
men
prior
myocardi
infarct
seroposit
mif
igg
receiv
either
azithromycin
mgday
day
placebo
found
patient
receiv
azithromycin
show
decreas
mif
igg
titer
lower
risk
secondari
advers
cardiac
event
patient
receiv
placebo
antibiot
regimen
use
gupta
colleagu
never
studi
treatment
c
pneumonia
infect
metaanalysi
random
trial
enrol
total
patient
publish
seven
trial
use
azithromycin
length
treatment
rang
mgday
day
mgwk
week
year
three
studi
use
roxithromycin
day
week
one
use
clarithromycin
mgday
day
one
use
gatifloxacin
complet
refer
list
avail
onlin
expert
consult
